Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment ...

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting ...

Elicera Therapeutics describes how CAR T cells armed with neutrophil-activatingprotein can improve cancer therapy by inducing ...

WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CLYM), announced today it will present and host investor ...

Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic ...

The companies Candid Therapeutics, ArsenalBio, and eGenesis bagged the biggest private biotech investments in September 2024.

Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to ...

Psoriasis is a multifactorial immune-mediated inflammatory disease. Its pathogenesis involves abnormal accumulation of neutrophils and T-cell related abnormalities. Pyroptosis is a type of regulated ...

Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...

Houston Methodist researchers will be part of a national consortium funded by an up to $49 million award from the U.S. Government's Advanced Research Projects Agency for Health (ARPA-H) to develop a ...

Those vaccinated had either one or two doses of Jynneos, the mpox vaccine. Comparing antibody and T-cell responses at the ...